OTC : DSNKY

Daiichi Sankyo Company, Limited

$17.52 USD

$0.19 (1.1%)

Volume
11.79K
Average Volume
325.47K
Market Capitalization
$31.88B
P/E Ratio
19.67
Dividend Yield
2.82%
Price Target
Year High
$27.50
Year Low
$14.98
Day High
—
Day Low
—
Payout Ratio
$0.49
Current Ratio
$2.42
Company Overview

OTC

Hiroyuki Okuzawa

Drug Manufacturers - General

Healthcare

DSNKY

20171

JP

USD

https://www.daiichisankyo.com

81 3 6225 1111

23381D102

N/A

Liquidity Metrics

0.18

2.42

1.64

0.51

0.49

Sales & Valuation

$2.25T

2.37

3.05

-99.09

-27.61

Profitability

$148.6

$275.55B

12.24%

12.41%

15.74%

6.49%

P/E Metrics

19.67

-1.98

-1.98

Analyst Price Target & Rating

Buy

4/5

2 Analysts

%

Financial Health Scores

2.96

5/9

$1.26T

$4.02T

$2.35T

$244B

Key Metrics (TTM)

$4.93T

2.32

14.58

2.42

15.74%

6.58%

5.07%

-1.00%

$1698.52

180 days

Company Executives
Name Title
Stuart Mackey Global Head of Business Development & Director
Tetsuya Ohira Corporate Officer, Head of Business Transformation & CTO
Matt Allegrucci Head of Global Compliance & Risk Management and Chief Compliance Officer
Hiroyuki Okuzawa President, Chief Executive Officer & Representative Director
Sunao Manabe Executive Chairperson
Joji Nakayama Senior Adviser
Takashi Matsumoto Sr. Exec Ofcr, Chief Corp Affairs Ofcr, Head of Global Corp Affairs & HR, CHRO & Director
Naoto Tsukaguchi Senior Executive Officer, Head of Global Legal & IP, GC
Joseph Kenneth Keller Head of Oncology Business Unit & Global Oncology Business and Director
Tomohiro Kodama Senior Executive Officer, Head of Global Corporate Planning & Management and CFO
Thierry Gruson Head of Global Oncology Marketing
Poll Results

No votes yet today — be the first to share your view!

About Daiichi Sankyo Company, Limited (OTC:DSNKY) Stock

Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise that encompasses the entire lifecycle of drug development, from pioneering research and development to manufacturing, importation, marketing, and worldwide distribution of its medicinal products. Its extensive and diverse portfolio features numerous key pharmaceutical offerings: Oncology: This includes trastuzumab deruxtecan (an anti-HER2 antibody-drug conjugate for cancer treatment), gefitinib for malignant tumors, bicalutamide for prostate cancer, and tamoxifen, an anti-breast cancer agent. Cardiovascular and Metabolic Health: The company provides teneligliptin and a combination of teneligliptin/canagliflozin for managing type 2 diabetes mellitus, along with colesevelam for both hypercholesterolemia and type 2 diabetes ... . Other notable products in this area are prasugrel, an antiplatelet agent; edoxaban, an anticoagulant; olmesartan, an antihypertensive; and pravastatin for hypercholesterolemia. Neurology and Pain Management: Offerings include mirogabalin for pain relief, lacosamide as an anti-epileptic agent, memantine for Alzheimer's disease, and loxoprofen, an anti-inflammatory analgesic. Bone Health: Denosumab is available for conditions like osteoporosis and other bone disorders. Gastrointestinal and Other Specialized Treatments: This category features esomeprazole for ulcer treatment, silodosin for dysuria, and ferric carboxymaltose and iron sucrose injections to address anemia. Infectious Diseases and Immunology: Daiichi Sankyo markets laninamivir for anti-influenza treatment, levofloxacin as an antibacterial agent, and a range of vaccines including adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. Beyond prescription medications, the company also supplies a variety of consumer healthcare products: Over-the-Counter Remedies: Lulu, a combination cold remedy, and Loxonin S, an antipyretic/anti-inflammatory analgesic. Dermatology and Personal Care: Transino, aimed at improving melasma and treating spots/freckles; Minon skincare products; and oral care solutions like Breath Labo and Clean Dental. Furthermore, Daiichi Sankyo's operations extend to pharmaceuticals and drugs for animals, cosmetics, medical equipment, various food products, drinking water, and active pharmaceutical ingredients (APIs) and intermediates. The company is also engaged in strategic collaborations, notably with Guardant Health to develop Guardant360 CDx, a companion diagnostic specifically for Enhertu in patients with advanced metastatic non-small cell lung cancer. Established in 1899, Daiichi Sankyo Company, Limited maintains its corporate headquarters in Tokyo, Japan.

Daiichi Sankyo (OTCMKTS:DSNKY) & Shuttle Pharmaceuticals (NASDAQ:SHPH) Head to Head Contrast

2026-07-22 01:15:09

Shuttle Pharmaceuticals (NASDAQ: SHPH - Get Free Report) and Daiichi Sankyo (OTCMKTS:DSNKY - Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, analyst recommendations, dividends, earnings and institutional ownership. Insider and Institutional Ownership 4.6% of Shuttle Pharmaceuticals

Daiichi Sankyo: Not Exciting Enough For This Market, Apparently

2026-07-01 12:02:17

Daiichi Sankyo maintains strong growth prospects, driven by its expanding antibody-drug conjugate (ADC) pipeline and disciplined oncology development. Trastuzumab deruxtecan remains a key growth driver, with ongoing label expansions and pivotal trial readouts expected in 2H 2026 for first-line lung cancer. Datopotamab deruxtecan and raludotatug deruxtecan have secured new approvals and promising data, broadening the company's oncology franchise beyond HER2.

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates

2026-05-22 09:30:00

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/NYSE: AZN) Datroway® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sank.

Daiichi Sankyo Company, Limited (DSNKY) Q4 2026 Earnings Call Transcript

2026-05-11 16:20:44

Daiichi Sankyo Company, Limited (DSNKY) Q4 2026 Earnings Call Transcript

Daiichi Sankyo Unveils New Five-Year Business Plan Focused on Oncology Leadership and Innovation

2026-05-11 02:30:00

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) today revealed its next Five-Year Business Plan (FY2026 - FY2030) that outlines how the company plans to deliver more than 2.3 trillion yen in oncology revenue by 2030 and be a global top five oncology company by 2035 as part of its larger 2035 Vision to be recognized as a “trusted healthcare innovator transforming the lives of people through science and technology.” The new Five-Year Business Plan reinforces the enduring purpose of Daiichi San.

Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program

2026-05-06 08:00:00

PARIS--(BUSINESS WIRE)--Waiv, formerly Owkin Dx, a Paris-based company catalyzing AI precision testing, today announced it has entered a collaboration with Daiichi Sankyo (TSE: 4568) to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) program. With deep expertise across diverse pathology and multimodal data, and a global data network spanning academic institutions, hospitals, and laboratories, Waiv has a proven track record delivering AI-powered biomarker solution.

Frequently Asked Questions

What is the current Daiichi Sankyo Company, Limited (DSNKY) stock price?

Daiichi Sankyo Company, Limited(OTC:DSNKY) stock price is $17.52 in the last trading session. During the trading session, DSNKY stock reached the peak price of $27.5 while $14.98 was the lowest point it dropped to. The percentage change in DSNKY stock occurred in the recent session was 1.1% while the dollar amount for the price change in DSNKY stock was $0.19.

DSNKY's industry and sector of operation?

The OTC listed DSNKY is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.

Who are the executives of DSNKY?

Stuart Mackey | Global Head of Business Development & Director
Tetsuya Ohira | Corporate Officer, Head of Business Transformation & CTO
Matt Allegrucci | Head of Global Compliance & Risk Management and Chief Compliance Officer
Hiroyuki Okuzawa | President, Chief Executive Officer & Representative Director
Sunao Manabe | Executive Chairperson

How many employees does DSNKY have?

Number of DSNKY employees currently stands at 20171. DSNKY operates from 3-5-1, Nihonbashi-honcho, Tokyo, TY 103-8426, JP.

Link for DSNKY official website?

Official Website of DSNKY is: https://www.daiichisankyo.com

How do I contact DSNKY?

DSNKY could be contacted at phone #81 3 6225 1111 and can also be accessed through its website. DSNKY operates from 3-5-1, Nihonbashi-honcho, Tokyo, TY 103-8426, JP.

How many shares of DSNKY are traded daily?

The average number of DSNKY shares traded daily for last 3 months was 325.47K.

What is the market cap of DSNKY currently?

The market value of DSNKY currently stands at $31.88B with its latest stock price at $17.52